Idiopathic Thrombocytopenic Purpura (ITP) Clinical Trial
Official title:
A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune bleeding disorder characterised by isolated low platelet counts. The aim of treating patients with ITP is to increase the platelet concentration and reduce the risk of bleeding. A number of controlled multi-centre studies have demonstrated that Intravenous Immunoglobulin (IVIg) therapy produces a rapid rise in platelet counts within a 24 to 72 hour period. This study will evaluate the efficacy and safety of Ig NextGen 10% in adult patients with ITP.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01437384 -
Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
|
Phase 1 | |
| Completed |
NCT00860600 -
Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients
|
Phase 2 | |
| Completed |
NCT01713738 -
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00161564 -
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
|
Phase 2 | |
| Terminated |
NCT00571467 -
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
|
Phase 1 |